Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
11.50
+0.12 (1.05%)
At close: Dec 19, 2025, 4:00 PM EST
11.60
+0.10 (0.87%)
After-hours: Dec 19, 2025, 5:56 PM EST
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
389.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | 75.00K | 2.00K | 2.74% |
| Jun 30, 2022 | 73.00K | 14.00K | 23.73% |
| Jun 30, 2021 | 59.00K | -43.00K | -42.16% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BNTC News
- 5 weeks ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 6 weeks ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 6 weeks ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 6 weeks ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 6 weeks ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire
- 3 months ago - Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 8 months ago - Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer - Seeking Alpha
- 9 months ago - Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering - GlobeNewsWire